Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Nanexa AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 0.95 |
52 Week High | SEK 3.69 |
52 Week Low | SEK 0.60 |
Beta | 1.67 |
11 Month Change | 6.76% |
3 Month Change | 21.85% |
1 Year Change | -73.30% |
33 Year Change | -82.70% |
5 Year Change | -92.48% |
Change since IPO | -90.32% |
Recent News & Updates
Recent updates
Shareholder Returns
NANEXA | SE Medical Equipment | SE Market | |
---|---|---|---|
7D | -2.9% | -6.2% | -7.2% |
1Y | -73.3% | -1.0% | 10.7% |
Return vs Industry: NANEXA underperformed the Swedish Medical Equipment industry which returned -2.8% over the past year.
Return vs Market: NANEXA underperformed the Swedish Market which returned 9.9% over the past year.
Price Volatility
NANEXA volatility | |
---|---|
NANEXA Average Weekly Movement | 10.8% |
Medical Equipment Industry Average Movement | 7.5% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: NANEXA's share price has been volatile over the past 3 months.
Volatility Over Time: NANEXA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 19 | David Westberg | www.nanexa.com |
Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia; NEX-20 for the treatment of multiple myeloma; and NEX-22 for the treatment of type 2 diabetes.
Nanexa AB (publ) Fundamentals Summary
NANEXA fundamental statistics | |
---|---|
Market cap | SEK 128.64m |
Earnings (TTM) | -SEK 70.62m |
Revenue (TTM) | SEK 59.73m |
2.2x
P/S Ratio-1.8x
P/E RatioIs NANEXA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NANEXA income statement (TTM) | |
---|---|
Revenue | SEK 59.73m |
Cost of Revenue | SEK 25.63m |
Gross Profit | SEK 34.10m |
Other Expenses | SEK 104.72m |
Earnings | -SEK 70.62m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 27, 2024
Earnings per share (EPS) | -0.52 |
Gross Margin | 57.09% |
Net Profit Margin | -118.23% |
Debt/Equity Ratio | 2.0% |
How did NANEXA perform over the long term?
See historical performance and comparison